FDA grants RPDD to CSTI-500 for treating pediatric Prader-Willi Syndrome
ConSynance Therapeutics' CSTI-500, an innovative Triple Monoamine Reuptake Inhibitor, has received FDA's Rare Pediatric Disease Designation for treating Prader-Willi Syndrome in children.
Food Insecurity and the Dangers of Infant Formula Dilution
Air pollution exposure during pregnancy linked to reduced lung function in childhood
These data highlighted the association of moderate air pollution exposure during pregnancy, infancy, and early childhood on pulmonary function at school age.
Demystifying Infant Formula
Merck's investigational RSV monoclonal antibody clesrovimab demonstrates positive results
Merck announced clesrovimab met all primary safety and efficacy endpoints, with additional detailed findings to be presented at an upcoming scientific congress.
FDA accepts remestemcel-L BLA to treat steroid-refractory acute graft versus host disease
With the acceptance of the BLA, a new PDUFA date of January 7, 2025 has been set.